This state is considering legislation that would threaten innovation and jobs. Learn more!
PILMA’s Labor Members
International Association of Fire Fighters
International Brotherhood of Boilermakers
International Association of Bridge, Structural, Ornamental and Reinforcing Ironworkers
Sheet Metal, Air, Rail and Transportation Workers
United Association
North America’s Building Trades Unions
International Union of Police Associations
International Union of Operating Engineers
International Brotherhood of Electrical Workers
PILMA’s Company Members
Pfizer
Eli Lilly & Co.
GlaxoSmithKline
Bayer Healthcare Pharmaceuticals
North America’s Building Trades Unions
Biogen
Novartis
Merck & Co.
PhRMA
Astellas
AstraZeneca LP
Johnson & Johnson Inc.
The pharmaceutical industry recognizes that the most highly skilled workers are needed to construct and maintain the highest quality research and manufacturing facilities. That is why they rely on North America’s Building Trades Unions to build and retrofit their facilities – they know they can depend on them to do the job on time, on budget and right the first time.
America’s Building Trades Unions spend more than $1 billion training their members each year. With state-of-the-art training facilities all over the country, the building trades are ready to meet the needs of today and the challenges of tomorrow. They lay the foundation that supports the biopharmaceutical industry’s quest to discover groundbreaking treatments and cures for a healthy America.
Important Issues to know:
trans·par·en·cy – Legislation requiring disclosure of proprietary and trade secret information, such as specific pricing, marketing and research and development information of biopharmaceuticals.
PILMA warns there are unintended consequences with this type of legislation, including chilling of innovation and capital construction projects with no clear benefits to patients.
im·por·ta·tion – Legislation that would allow the bringing of biopharmaceuticals from other counties into the U.S.
PILMA believes that there is no way to guarantee the safety and ingredients of imported medicines, further, this practices will erode U.S. jobs in the biopharmaceutical industry.
“The industry relies on the trades to build, maintain and retrofit their facilities. In order to meet the rigorous standards of the biopharmaceutical manufacturers, our training centers align curriculum to the need of the industry. The development of new life saving drugs depends on this key relationship.”
Eric Dean
PILMA Chairman
President, Ironworkers International
“Our commitment is to the safety and quality of the products that we sell. We need companies with strong reputations and a qualified workforce. When you pay for quality, the investment comes back to you.”
Don Bohn
PILMA Vice Chairman
VP Global Government Affairs, Johnson & Johnson